| 地塞米松玻璃体内植入剂治疗白内障术后人工晶状体眼黄斑囊样水肿的短期疗效观察 |
| |
| 引用本文： | 修立恒,赵静,钱婷丽,成仲夏. 地塞米松玻璃体内植入剂治疗白内障术后人工晶状体眼黄斑囊样水肿的短期疗效观察[J]. 眼科新进展, 2021, 0(12): 1175-1178. DOI: 10.13389/j.cnki.rao.2021.0245 |
| |
| 作者姓名： | 修立恒 赵静 钱婷丽 成仲夏 |
| |
| 作者单位： | 610081 四川省成都市,成都大学附属医院眼科（修立恒,钱婷丽,成仲夏）;550004 贵州省贵阳市,贵州医科大学附属医院眼科（赵静） |
| |
| 摘 要： | 目的 观察地塞米松玻璃体内植入剂(Ozurdex)治疗白内障术后人工晶状体眼黄斑囊样水肿(PCME)的疗效及安全性.方法 回顾性分析14例(16眼)PCME患者的临床资料.所有患眼均接受玻璃体内注射地塞米松玻璃体内植入剂0.7 mg的治疗,治疗后随访6个月,随访期间若发现PCME复发,则再次注射地塞米松玻璃体内植入剂....
|
| 关 键 词： | 地塞米松玻璃体内植入剂 人工晶状体眼 黄斑囊样水肿 |
Short-term outcomes of dexamethasone intravitreal implant in the treatment of pseudophakic cystoid macular edema after cataract surgery |
| |
| XIU Liheng,ZHAO Jing,QIAN Tingli,CHENG Zhongxia. Short-term outcomes of dexamethasone intravitreal implant in the treatment of pseudophakic cystoid macular edema after cataract surgery[J]. Recent Advances in Ophthalmology, 2021, 0(12): 1175-1178. DOI: 10.13389/j.cnki.rao.2021.0245 |
| |
| Authors: | XIU Liheng ZHAO Jing QIAN Tingli CHENG Zhongxia |
| |
| Affiliation: | 1.Department of Ophthalmology,Affiliated Hospital of Chengdu University,Chengdu 610081,Sichuan Province,China2.Department of Ophthalmology,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,Guizhou Province,China |
| |
| Abstract: | Objective To evaluate the efficacy and safety of dexamethasone intravitreal implant (Ozurdex) in the treatment of pseudophakic cystoid macular edema (PCME) after cataract surgery. Methods The clinical data of 14 patients (16 eyes) with PCME were retrospectively analyzed. All eyes were intravitreally injected with 0.7 mg of dexamethasone intravitreal implant. During the follow-up 6 months, in case of the recurrence of PCME, dexamethasone intravitreal implant was injected again. The best corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) were recorded and compared preoperatively, 1 month, 3 months, and 6 months postoperatively. Results The BCVA (logMAR) before treatment, at 1, 3 and 6 months after treatment was 0.61±0.17, 0.15±0.10, 0.14±0.10, and 0.12±0.10, respectively, and the CMT was (540.38±76.10) μm, (229.13±13.27) μm, (227.13±13.32) μm, and (225.56±14.88) μm, respectively. Compared with the preoperative conditions, the BCVA of all eyes significantly improved and CMT significantly reduced at 1 month, 3 months, and 6 months after treatment (all P<0.001), while the IOP showed no statistical difference (F=0.751, P=0.087). During the 6-month follow-up, only one eye underwent intravitreal injection of dexamethasone twice. IOP increased slightly in two eyes and then returned to normal after IOP-lowering treatment. All patients had no complications related to drug and eye treatment during follow-up. Conclusion Dexamethasone intravitreal implant has a significant effect in the treatment of PCME in a short time. |
| |
| Keywords: | dexamethasone intravitreal implant pseudophakic eye cystoid macular edema |
|
| 点击此处可从《眼科新进展》浏览原始摘要信息 |
|
点击此处可从《眼科新进展》下载免费的PDF全文 |
|
